Human LPLUNC1 is a secreted product of goblet cells and minor glands of the respiratory and upper aerodigestive tracts
- 737 Downloads
Long PLUNC1 (LPLUNC1, C20orf114) is a member of a family of poorly described proteins (PLUNCS) expressed in the upper respiratory tract and oral cavity, which may function in host defence. Although it is one of the most highly expressed genes in the upper airways and has been identified in sputum and nasal secretions by proteomic studies, localisation of LPLUNC1 protein has not yet been described. We developed affinity purified antibodies and localised the protein in tissues of the human respiratory tract, oro- and nasopharynx. We have complemented these studies with analysis of LPLUNC1 expression in primary human lung cell cultures and used Western blotting to study the protein in cell culture secretions and in BAL. LPLUNC1 is a product of a population of goblet cells in the airway epithelium and nasal passages and is also present in airway submucosal glands and minor glands of the oral and nasal cavities. The protein is not expressed in peripheral lung epithelial cells. LPLUNC1 is present in bronchoalveolar lavage fluid as two glycosylated isoforms and primary airway epithelial cells produce identical proteins as they undergo mucociliary differentiation. Our results suggest that LPLUNC1 is an abundant, secreted product of goblet cells and minor mucosal glands of the respiratory tract and oral cavity and suggest that the protein functions in the complex milieu that protects the mucosal surfaces in these locations.
KeywordsLPLUNC1 Airway Glands Goblet cells Immunohistochemistry Innate immunity
Palate lung nasal epithelium clone (PLUNC) was first described in the nasal epithelium of the mouse embryo and the trachea/bronchi of adult mice (Weston et al. 1999). We made the key observation that PLUNC belongs to a family of nine genes in a single locus on human chromosome 20q11 (Bingle and Craven 2002, 2004; Bingle et al. 2004) and showed that they make up the largest branch of a lipid transfer protein family that includes phospholipid transfer protein (PLTP), cholesterol ester transfer protein (CETP), bactericidal permeability increasing protein (BPI) and LPS-binding protein (LBP) (Bingle et al. 2004). Structural similarity across the PLUNC/BPI family suggests that these proteins function by binding lipid molecules (Beamer et al. 1997; Bingle and Craven 2004; Masson et al. 2009) and this led us to suggest that PLUNCs may share host defence functions with BPI and LBP (Bingle and Craven 2002). It is now generally accepted that PLUNCs fulfil a host defence function (Canny and Levy 2008) but in reality compelling functional data on members of this family has not been forthcoming. However, our genomic studies have shown that rapid evolution has produced a distinct repertoire of PLUNC genes in mammals characterised by low sequence similarity, an observation that is often found in host defence protein families (Bingle et al. 2004; Wheeler et al. 2007). The limited data which exists indicates that these genes are predominantly expressed in locations where innate defence is a major requirement, namely in the nasal, tracheal and bronchial passages as well as in major salivary glands and minor mucosal glands of the oral cavity (Weston et al. 1999; Bingle and Craven 2002; Wheeler et al. 2002; Sung et al. 2002; Di et al. 2003; LeClair et al. 2004; Bingle et al. 2004; Geetha et al. 2005; Wheeler et al. 2007). The prototypic two BPI-domain-containing protein, LPLUNC1 (or C20orf114), along with the founding family member SPLUNC1 (PLUNC), are highly expressed in the upper respiratory tract (Weston et al. 1999; Bingle and Bingle 2000; Bingle and Craven 2002; Di et al. 2003) and are attracting increased attention through their identification in many genomic and proteomic studies (Barnes et al. 2008). Importantly, LPLUNC1 and SPLUNC1 are two of the members of this family that are present in all mammals (Bingle et al. 2004; Wheeler et al. 2007). There are no published studies on the function and localisation of LPLUNC1, however, proteomic studies have identified it in nasal secretions, bronchoalveolar lavage (BAL) and sputum (Casado et al. 2005; Wu et al. 2005; Nicholas et al. 2006) and shown that it is a major secreted product of cultured tracheobronchial epithelial (TBE) cells (Candiano et al. 2007; Kesimer et al. 2009).
In the present study, we have generated and characterised antibodies specific to human LPLUNC1 and used these to carry out an extensive analysis of LPLUNC1 expression in the respiratory tract and oral cavity and have also studied the production and localisation of the protein in differentiated primary TBE cells cultured at the air–liquid interface (ALI).
Materials and methods
Generation and characterisation of human-specific LPLUNC1 antibodies
Two affinity purified, peptide-specific, polyclonal antibodies were generated in rabbits against human LPLUNC1 by Eurogentec (Seraing, Belgium) using established methods. The peptide sequences used corresponded to amino acids, 139–154: (TIRMDTSASGPTRLV) located in the first BPI domain of LPLUNC1 (for LPLUNC1 antibody “A”) and the second to amino acids, 472–484: (ASLWKPSSPVSQ) at the extreme C-terminus of the protein in the second BPI domain (for LPLUNC1 antibody “B”). These peptides were chosen so as to have minimal sequence conservation between man and mouse (Supplementary Figure S1) and no similarity with other members of the PLUNC family. Bioinformatic analysis also showed that these epitopes had no significant sequence identity with any other human proteins.
Expression clones for LPLUNC1 proteins (both mouse and human) in pcDNA5-frt-V5-His-Topo (Invitrogen) were used in the characterisation of the antibodies. Constructs were used for coupled in vitro transcription/translation (IVT) reactions (Promega) as previously described (Bingle et al. 2005, 2007) and to generate CHO cell lines stably expressing the proteins. Expression clones for SPLUNC1 and SPLUNC2, produced in the same vector, were used as controls (Bingle et al. 2005, 2009). 2 μl aliquots of IVT reactions or 5 μl of serum free conditioned medium from CHO cell lines stably expressing PLUNC proteins, were run on replicate SDS-PAGE gels and Western blotted using either an anti-V5 antibody (1:500 dilution) (Invitrogen) or the specific LPLUNC1 antibodies (1:2,000 dilution) and detected as described (Bingle et al. 2005, 2009).
The tissue used in this study was collected with ethical approval on a fully anonymous basis only and thus we have no further patient details. Serial sections (4 μm) were cut from formalin-fixed and paraffin-embedded tissue as described (Bingle et al. 2005, 2006). For normal pulmonary tissues, sections were taken so as to be as representative of normal architecture as possible, although as all tissues were removed for medical reasons there was some evidence of disease in some sections. Sections from the major bronchi and peripheral lung were cut from >15 cases of histologically “normal” lung. The slides were stained as previously described (Bingle et al. 2005, 2007, 2009). LPLUNC1 antibodies were used at a final dilution of 1:100 (LPLUNC1A) or 1:600 (LPLUNC1B) following antigen retrieval using tri-sodium citrate in a microwave for 8 min (Bingle et al. 2007). Control sections were stained in the absence of either primary or secondary antibody. Antibodies against human SPLUNC1 (final dilution 1:300) and human mucin 5AC (MUC5AC, a gift of Dr David Thornton, University of Manchester, final dilution 1:500) were used as described (Campos et al. 2004; Bingle et al. 2007; Kirkham et al. 2008).
Cell culture, RNA extraction and RT-PCR
Human TBE cells were cultured at an ALI as described previously (Nlend et al. 2002) using protocols approved by the local institutional review board. RNA extraction, RT-PCR and product validation was performed as described (Bingle et al. 2006, 2007) using the following primers for LPLUNC1 F 5′ CCC TGC CCA ATC TAG TGA AA 3′, LPLUNC1 R 5′ TCA CCT TTC CCT GTG AGT CG 3′ and Actin F 5′ CTA CAA TGA GCT GCG TGT GG 3′, Actin R 5′ AAG GAA GGC TGG AAG AGT GC 3′. The SPLUNC1, SLPI, Elafin and CCSP primers have been described previously (Bingle et al. 2006, 2007). RT-minus PCR reactions were run as negative controls for all experiments.
After harvesting apical secretions with PBS, ALI TBE culture filters were fixed with 50% acetone/50% methanol for 2 min at −20°C, blocked with 1% BSA for 1 h, and incubated overnight with anti-LPLUNC1 antibodies (1:500 PBS–1% BSA) at 4°C. All subsequent steps were done at room temperature. After washing with PBS (3×), filters were incubated with a polyclonal goat anti-rabbit IgG labelled with Alexa Fluor 555 (1:5,000 PBS–1% BSA, Molecular Probes) for 1 h. Culture filters were sliced and incubated with either mouse anti-human MUC5AC IgG (1:100 PBS–1% BSA, Chemicon International) or mouse anti-human acetylated tubulin IgG (1:500 PBS–1% BSA, Sigma) for visualization of mucous or ciliated cells, respectively. In addition, some slides were incubated with goat anti-human SPLUNC1 IgG (1:100 PBS–1% BSA, R&D Systems). Appropriate second antibodies labelled with either Alexa Fluor 488, Alexa Fluor 555 or Cy5 (1:500 in PBS–1% BSA, all from Molecular Probes) were added for 1 h. 4′-6-Diamidino-2-phenylindole (DAPI, 1:1,000) was added to the last wash for nuclear staining. Filters were placed in glass slides for visualization with a Zeiss LSM-510 confocal laser-scanning microscope in the University of Miami Analytical Imaging Core Facility.
Western blotting of cell culture secretions and Bronchoalveolar lavage
Apical secretions were collected, every 2–3 days, from differentiated TBE cells cultured at the ALI, by washing each well of a 12 well plate with 100 μl of PBS. Pooled samples were centrifuged at 600×g to remove cellular debris and 5 μl aliquots used for Western blotting as outlined above. BAL samples were obtained by instilling 60 ml of normal saline in either the non-diseased middle lobe or lingula from subjects undergoing clinically indicated bronchoscopy, under a protocol approved by the University of Miami’s Institutional Review Board. 15 μl of BALs were subjected to Western blotting. Aliquots of ALI cell culture secretions and BAL were digested overnight with PNGase F (NEB) according to the manufacturer’s instructions and Western blotted.
Validation of LPLUNC1 antibodies
LPLUNC1 is localised in a population of goblet cells in the upper airways and in submucosal and minor mucosal glands
In the trachea and central bronchi the most prominent staining was seen in a population of what appeared to be surface goblet cells and in sub-mucosal glands (Fig. 2d). In a number of cases we noted the most intense staining in cells of the submucosal duct and in epithelial regions where the duct entered the airway. Staining was also seen in epithelial cells of smaller airways (those without cartilage and submucosal glands, Fig. 2e, f). Importantly LPLUNC1 staining was never seen in the alveolar epithelium (Fig. 2f) nor were we able to detect specific staining in endothelial cells or in inflammatory cells, including alveolar macrophages (results not shown). To ensure specificity of the antibodies we stained closely cut sections with both antibodies. They both stained cells of the seromucous tubules in submucosal glands (Fig. 2h, i) suggesting that they both recognise the same protein. Mucous cells in the airway submucosal glands did not stain. Additional antibodies to SPLUNC2 generated and purified at the same time (Bingle et al. 2009) as the LPLUNC1 antibodies failed to show any staining in the lung sections (results not shown) and sections stained without the addition of primary or secondary antibodies were also negative for staining (results not shown) further supporting our belief that these antibodies are valid reagents for the specific detection of human LPLUNC1.
LPLUNC1 is secreted from goblet cells in differentiated TBE cell cultures as a glycosylated protein
Since our original description of LPLUNC1 as the prototypic two BPI-domain-containing PLUNC family member (Bingle and Craven 2002), no studies have addressed the localisation or secretion of the protein. In the present study, we used highly specific antibodies to localise expression of LPLUNC1 in the upper respiratory tract, nasal and oral cavities. We took great care to ensure that the antibodies recognise only LPLUNC1 by choosing peptides that had no sequence conservation with other PLUNC family members and that are not conserved in orthologues from rodent species (Bingle and Craven 2002; Bingle et al. 2004). Furthermore these epitopes are not present in any other mouse protein. The fact that both antibodies stained proteins in the same cells in the tissue sections (Fig. 2) and recognised the same protein bands in Western blotting of ALI secretions and BAL fluid, lend further support of our suggestion that they are recognising human LPLUNC1 specifically. The antibodies indicate that the protein is abundantly expressed in a population of goblet cells in the upper respiratory tract and that the protein is strongly expressed in airway submucosal glands and a range of minor glands present in the oral cavity and nasopharynx. Our Western blotting studies, which identified the protein in BAL fluid, provide strong evidence for secretion of LPLUNC1 into mucosal lining fluids and also supports a number of proteomic studies that have reported the protein in BAL, sputum and in nasal secretions (Casado et al. 2005; Wu et al. 2005; Nicholas et al. 2006; Candiano et al. 2007; Kesimer et al. 2009).
Although LPLUNC1 appears to be present in a population of goblet cells in the airways in these non-diseased samples it is not present in all goblet cells and is most commonly seen in those that are closely associated with the junction of the submucosal gland duct and within the duct itself. Thus, LPLUNC1 is not a surrogate marker for airway goblet cells especially as in the normal airways there are clearly a significant number of MUC5AC containing cells that are negative for LPLUNC1. It is possible that the lack of staining seen in some goblet cells may reflect the fact that the protein has been secreted into the airway lumen. Further studies are required to identify if these LPLUNC1 positive goblet cells exhibit any additional unique characteristics. Mouse lplunc1 RNA has been shown to be elevated in multiple mouse models associated with increased goblet cells (Barnes et al. 2008) and we are presently evaluating if all airway goblet cells human diseased human lung tissues stain for the protein.
Importantly our studies have shown that LPLUNC1 is present in a different airway cell population than the related protein, SPLUNC1, previously shown to be present in non-ciliated, non-goblet-cells (Bingle et al. 2005, 2007). It is clear that these cells do not express LPLUNC1. The situation is somewhat different in some minor mucosal glands where, for example, the minor seromucous glands surrounding the palatine tonsils co-express both proteins. Interestingly these particular glands also express SPLUNC2, the major salivary gland expressed family member (Bingle et al. 2009), suggesting that at least in some situations minor gland cells contain the appropriate regulatory machinery to support expression of a range of different PLUNCs. Our analysis has focused on tissues of the respiratory tract and oral cavities as this appears to be the predominant site of LPLUNC1 expression (Bingle and Craven 2002). Analysis of multiple expression data sets do not suggest that other tissues that contain abundant goblet cells, for example the intestines, are major sites of LPLUNC1 expression. We did report that stomach expressed LPLUNC1 (Bingle and Craven 2002) and that expression was also seen in the developing mouse gut (LeClair et al. 2004). More recently LPLUNC1 expression has been shown to be increased in biopsies form patients with acute cholera (Flach et al. 2007). Further studies are required to establish that these tissues do produce the protein.
The mechanisms that govern expression of PLUNCs have not been elucidated, in part because of the lack of suitable cell lines in which to perform these studies. We have reported SPLUNC1 NCI-H647 cells (Bingle and Bingle 2000), but have been unable to find an established cell line that supports expression of LPLUNC1 (results not shown). Our analysis of the ALI TBE cells suggests that this model system may be a useful one in which to uncover regulatory mechanisms as they express both LPLUNC1 and SPLUNC1 and levels of gene expression can be modulated by the differentiation status of the cultures. The ALI cultures further mimicked the situation in the airways in vivo as LPLUNC1 was found in a population of ‘goblet’ cells, as judged by the co-expression of MUC5A/C, but expression of the two markers was not always seen in the same cells. However, in contrast to this, in vitro expression of LPLUNC1 was seen in a subpopulation of cells that also produce SPLUNC1 suggesting that this culture model may support some uncoupling of gene expression not seen in “normal” airways. SPLUNC1 was still seen in more cells than LPLUNC1. These studies confirm that ALI TBE cells maybe useful tools in which to study the regulation of LPLUNC1 and SPLUNC1 gene expression.
The LPLUNC1 secreted by TBE cells was glycosylated in a manner similar to that found in BAL samples. N-glycosylated isoforms of LPLUNC1 have also been described in saliva (Ramachandra et al. 2008) and it seems likely that this post-translational modification, and thus the glycosylation status, is functionally important for the biological activity of LPLUNC1. Previous studies have also shown that other PLUNCs, including both SPLUNC1 and the salivary enriched protein, SPLUNC2/psp, are also subjected to significant post-translational modifications (Mirels et al. 1998; Ghafouri et al. 2004; Bingle et al. 2009) suggesting that it is a common feature of this family of proteins. Our Western blotting studies also suggest that LPLUNC1 is not subject of significant proteolytic processing in normal airways secretions. We could not detect any smaller proteolytic fragments either the ALI secretions or the BAL fluid when samples were probed with either antibody. It remains to be seen if a similar situation is seen in samples from lung disease.
Our studies suggest that LPLUNC1 is expressed in a goblet cell population and thus it seems likely that alterations of LPLUNC1 localisation and production may be found in lung diseases associated with increase numbers of goblet cells. This suggestion is further supported by the observation that Lplunc1 is elevated in multiple array studies of mouse models of lung diseases (Barnes et al. 2008) in which goblet cell number are known to be increased. We have previously reported an increase in SPLUNC1 protein production by airway epithelial cells in severe cystic fibrosis (Bingle et al. 2007) due to a phenotypic alteration in the airways in such patients and are presently evaluating LPUNC1 expression in this and a series of other human disease sample sets.
In summary, we have localised LPLUNC1 to a subset of goblet cells within the airways, in the submucosal glands of the upper airways, as well as in minor glands in the nose, sinuses, posterior tongue and tonsil. LPLUNC1 is present in BAL fluid as a glycoprotein and we have shown that expression and secretion of the protein is increased in TBE cells as they undergo mucociliary differentiation in culture. Although the function of LPLUNC1 remains to be resolved, our results suggest that the protein functions in the complex milieu that protects the mucosal surfaces in these locations.
This work was funded by the Wellcome Trust. We are grateful to Moira Whyte and Thais Mauad for helpful discussions and advice on this manuscript. The MUC5A/C antibody was a gift from David Thornton, University of Manchester, UK.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.